Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (541-550 of 662) with videos related to

Pageof 67
Sort By:
Cell Reports|June 14, 2018
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsKatherine Sullivan-Reed, Elisabeth Bolton-Gillespie, Yashodhara Dasgupta, et al.
Leukemia|July 5, 2022
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosisAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.
The Journal of Clinical Investigation|December 5, 2017
STAT5BN642H is a driver mutation for T cell neoplasiaHa Thi Thanh Pham, Barbara Maurer, Michaela Prchal-Murphy, et al.
Genes, Chromosomes & Cancer|September 25, 2018
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significanceJulie Schanz, Francesc Solé, Mar Mallo, et al.
Nature Reviews. Cancer|October 12, 2012
Cancer stem cell definitions and terminology: the devil is in the detailsPeter Valent, Dominique Bonnet, Ruggero De Maria, et al.
Blood|October 4, 2017
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemiaBernd Boidol, Christoph Kornauth, Emiel van der Kouwe, et al.
Leukemia|February 24, 2018
Pharmacologic inhibition of STAT5 in acute myeloid leukemiaBettina Wingelhofer, Barbara Maurer, Elizabeth C Heyes, et al.
Annals of Hematology|January 17, 2009
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic SyndromesPeter Valent, Wolf-Karsten Hofmann, Guntram Büsche, et al.
Ebiomedicine|December 6, 2017
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus ProposalPeter Valent, Cem Akin, Michel Arock, et al.
The World Allergy Organization Journal|January 4, 2013
ICON: Eosinophil DisordersPeter Valent, Amy D Klion, Lanny J Rosenwasser, et al.
Pageof 67

Showing results (541-550 of 662) with videos related to

Sort By:
Pageof 67
Cell Reports|June 14, 2018
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsKatherine Sullivan-Reed, Elisabeth Bolton-Gillespie, Yashodhara Dasgupta, et al.
Leukemia|July 5, 2022
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosisAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.
The Journal of Clinical Investigation|December 5, 2017
STAT5BN642H is a driver mutation for T cell neoplasiaHa Thi Thanh Pham, Barbara Maurer, Michaela Prchal-Murphy, et al.
Genes, Chromosomes & Cancer|September 25, 2018
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significanceJulie Schanz, Francesc Solé, Mar Mallo, et al.
Nature Reviews. Cancer|October 12, 2012
Cancer stem cell definitions and terminology: the devil is in the detailsPeter Valent, Dominique Bonnet, Ruggero De Maria, et al.
Blood|October 4, 2017
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemiaBernd Boidol, Christoph Kornauth, Emiel van der Kouwe, et al.
Leukemia|February 24, 2018
Pharmacologic inhibition of STAT5 in acute myeloid leukemiaBettina Wingelhofer, Barbara Maurer, Elizabeth C Heyes, et al.
Annals of Hematology|January 17, 2009
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic SyndromesPeter Valent, Wolf-Karsten Hofmann, Guntram Büsche, et al.
Ebiomedicine|December 6, 2017
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus ProposalPeter Valent, Cem Akin, Michel Arock, et al.
The World Allergy Organization Journal|January 4, 2013
ICON: Eosinophil DisordersPeter Valent, Amy D Klion, Lanny J Rosenwasser, et al.
Pageof 67